Vakzine Projekt Management GmbH (VPM) announces that the first clinical center in South Africa has been initiated in a large phase III trial (priMe) to assess the efficacy and safety of the novel TB vaccine – VPM1002 – in comparison with BCG in healthy newborn infants. The clinical centers in Tanzania, Uganda and Gabon will follow in the next weeks.
Press release on VPM’s COVID-19 study published in “Neue Presse”
“MHH testet Corona-Impfstoff – besser als Biontech & Co.?”
First vaccinee enrolled in a large phase III trial against tuberculosis in a Pan-African setting
Vakzine Projekt Management GmbH (VPM) announces that the first participant has been enrolled
Tdap study enters phase III
Following the successful completion of phase II part of the Tdap study (tetanus, diphtheria and pertussis) Tadeus, phase III part will commence this week,
30 Million Euro Loan from the EIB for TB
VPM receives 30 Million Euro Funding from the European Investment Bank for VPM1002 tuberculosis vaccine development in Africa.
Hope for the elderly in the corona pandemic
First participants receive VPM1002 in a late-stage phase III clinical trial in Germany.
SARS-CoV-2 study kicks off in Germany
First participant enrolled in Phase III clinical trial of VPM1002 focused on healthcare workers battling the COVID-19 pandemic.
Immune boost against the corona virus
In Germany, a vaccine candidate will be tested for its effectiveness against infections with the novel corona virus.
First volunteer enrolled
Vakzine Projekt Management GmbH: First volunteer enrolled in Phase II/III Study of SIIPL Tdap vaccine in Comparison with Boostrix® in Healthy Participants.
Modified TB vaccine as a therapy for bladder cancer
Press release on February 20, 2020: Modified tuberculosis vaccine as a therapy for cancer of the bladder. A therapy with VPM1002 is effective for bladder cancer patients. Please klick here for the whole release!